Skip to main content

Table 3 Mean serum creatinine at baseline, week 16 and corresponding differences with confidence intervals

From: Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats

Creatinine (mg/dl)BaselineWeek 16Difference (%)
Placebo0.44 ± 0.050.45 ± 0.054 ± 13
Everolimus0.44 ± 0.040.42 ± 0.04− 4 ± 10
Placebo + [177Lu]Lu-DOTA-TATE0.45 ± 0.050.58 ± 0.1626 ± 25
Everolimus + [177Lu]Lu-DOTA-TATE0.48 ± 0.040.46 ± 0.05− 1 ± 16